Literature DB >> 21297038

Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study.

Mieke Van Hemelrijck1, Lars Holmberg, Hans Garmo, Niklas Hammar, Göran Walldius, Elisa Binda, Mats Lambe, Ingmar Jungner.   

Abstract

OBJECTIVE: To study levels of C-reactive protein (CRP) and leukocytes, as inflammatory markers, in the context of cancer risk.
METHODS: From the Apolipoprotein MOrtality RISk (AMORIS) study, we selected 102,749 persons with one measurement and 9,273 persons with three repeated measurements of CRP and leukocytes. Multivariate Cox proportional hazards regression was applied to categories of CRP (<10, 10-15, 15-25, 25-50, >50 g/L) and quartiles of leukocytes. An inflammation-based predictive score (IPS) indicated whether someone had CRP levels of more than 10 mg/L combined with leukocytes of more than 10×10(9)/L. Reverse causality was assessed by excluding those with less than 3, 5, or 7 years of follow-up. To analyze repeated measurements of CRP and leukocytes, the repeated IPS (IPSr) was calculated by adding the IPS of each measurement.
RESULTS: In the cohort with one measurement, there was a positive trend between CRP and risk of developing cancer, with the lowest category being the 0.99 (0.92-1.06), 1.28 (1.11-1.47), 1.27 (1.09-1.49), and 1.22 (1.01-1.48) for the second to fifth categories, respectively. This association disappeared when excluding those with follow-up of less than 3, 5, or 7 years. The association between leukocytes and cancer was slightly stronger. In the cohort with repeated measurements, the IPSr was strongly associated with cancer risk: 1.87 (1.33-2.63), 1.51 (0.56-4.06), and 4.46 (1.43-13.87) for IPSr=1, 2, and 3 compared with IPSr=0. The association remained after excluding those with follow-up of less than 1 year. CONCLUSIONS AND IMPACT: Our large, prospective cohort study adds evidence for a link between inflammatory markers and cancer risk by using repeated measurements and ascertaining reverse causality. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21297038      PMCID: PMC3078551          DOI: 10.1158/1055-9965.EPI-10-1190

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  30 in total

1.  Exploring a cancer biomarker: the example of C-reactive protein.

Authors:  Paolo Boffetta
Journal:  J Natl Cancer Inst       Date:  2010-01-07       Impact factor: 13.506

Review 2.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.

Authors:  Alberto Mantovani; Silvano Sozzani; Massimo Locati; Paola Allavena; Antonio Sica
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

3.  Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts.

Authors:  Isabel dos Santos Silva; Bianca L De Stavola; Costanza Pizzi; Tom W Meade
Journal:  Int J Epidemiol       Date:  2010-03-24       Impact factor: 7.196

4.  Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).

Authors:  Ingar Holme; Are H Aastveit; Niklas Hammar; Ingmar Jungner; Göran Walldius
Journal:  Atherosclerosis       Date:  2010-08-19       Impact factor: 5.162

5.  Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose.

Authors:  Mieke Van Hemelrijck; Hans Garmo; Lars Holmberg; Göran Walldius; Ingmar Jungner; Niklas Hammar; Mats Lambe
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

6.  Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer.

Authors:  Kristine H Allin; Stig E Bojesen; Børge G Nordestgaard
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

7.  Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis.

Authors:  Katriina Heikkilä; Ross Harris; Gordon Lowe; Ann Rumley; John Yarnell; John Gallacher; Yoav Ben-Shlomo; Shah Ebrahim; Debbie A Lawlor
Journal:  Cancer Causes Control       Date:  2008-08-15       Impact factor: 2.506

8.  Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes.

Authors:  R Ganss; D Hanahan
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

9.  Physical activity, white blood cell count, and lung cancer risk in a prospective cohort study.

Authors:  Brian L Sprague; Amy Trentham-Dietz; Barbara E K Klein; Ronald Klein; Karen J Cruickshanks; Kristine E Lee; John M Hampton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10       Impact factor: 4.254

10.  A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer.

Authors:  L M Forrest; D C McMillan; C S McArdle; W J Angerson; K Dagg; H R Scott
Journal:  Br J Cancer       Date:  2005-05-23       Impact factor: 7.640

View more
  24 in total

1.  Plasma C-reactive protein and risk of breast cancer in two prospective studies and a meta-analysis.

Authors:  Jun Wang; I-Min Lee; Shelley S Tworoger; Julie E Buring; Paul M Ridker; Bernard Rosner; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-05-20       Impact factor: 4.254

2.  Urinary phytoestrogens and cancer, cardiovascular, and all-cause mortality in the continuous National Health and Nutrition Examination Survey.

Authors:  Michael K Reger; Terrell W Zollinger; Ziyue Liu; Josette Jones; Jianjun Zhang
Journal:  Eur J Nutr       Date:  2015-05-06       Impact factor: 5.614

3.  An Adolescent and Early Adulthood Dietary Pattern Associated with Inflammation and the Incidence of Breast Cancer.

Authors:  Holly R Harris; Walter C Willett; Rita L Vaidya; Karin B Michels
Journal:  Cancer Res       Date:  2017-03-01       Impact factor: 12.701

4.  Association between high-sensitivity C-reactive protein (hsCRP) and change in mammographic density over time in the SWAN mammographic density subcohort.

Authors:  Kunlanat Makboon; Ellen B Gold; Danielle J Harvey; Lesley M Butler; Laurel A Habel
Journal:  Cancer Causes Control       Date:  2015-01-21       Impact factor: 2.506

5.  Chronic inflammation and risk of lung cancer in older adults in the health, aging and body composition cohort study.

Authors:  Joshua Demb; Esther K Wei; Monika Izano; Stephen Kritchevsky; Helen Swede; Anne B Newman; Michael Shlipak; Tomi Akinyemiju; Steven Gregorich; Dejana Braithwaite
Journal:  J Geriatr Oncol       Date:  2018-08-03       Impact factor: 3.599

6.  Gamma-glutamyl transferase and C-reactive protein as alternative markers of metabolic abnormalities and their associated comorbidites: a prospective cohort study.

Authors:  Jennifer C Melvin; Crystal Rodrigues; Lars Holmberg; Hans Garmo; Niklas Hammar; Ingmar Jungner; Göran Walldius; Mats Lambe; Wayel Jassem; Mieke Van Hemelrijck
Journal:  Int J Mol Epidemiol Genet       Date:  2012-11-15

7.  Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study.

Authors:  Anna E Prizment; Aaron R Folsom; Jill Dreyfus; Kristin E Anderson; Kala Visvanathan; Corinne E Joshu; Elizabeth A Platz; James S Pankow
Journal:  Cancer Causes Control       Date:  2013-09-14       Impact factor: 2.506

8.  C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis.

Authors:  Bo Zhou; Jing Liu; Ze-Mu Wang; Tao Xi
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

9.  Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value.

Authors:  Michael J Walker; Cong Zhou; Alison Backen; Maria Pernemalm; Andrew J K Williamson; Lynsey J C Priest; Pek Koh; Corinne Faivre-Finn; Fiona H Blackhall; Caroline Dive; Anthony D Whetton
Journal:  EBioMedicine       Date:  2015-06-19       Impact factor: 8.143

10.  Iron metabolism and risk of cancer in the Swedish AMORIS study.

Authors:  Anjali Gaur; Helen Collins; Wahyu Wulaningsih; Lars Holmberg; Hans Garmo; Niklas Hammar; Göran Walldius; Ingmar Jungner; Mieke Van Hemelrijck
Journal:  Cancer Causes Control       Date:  2013-05-07       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.